Could psychedelics help you to drink less alcohol? Our new study aims to find out
Psychedelics like LSD and psilocybin (the active ingredient in magic mushrooms) are gaining increasing attention in psychiatry. Studies suggest they may offer therapeutic benefits for conditions such as depression, anxiety, obsessive–compulsive disorder, eating disorders and addiction.
Our research team is investigating whether N,N-dimethyltryptamine (DMT), a fast-acting psychedelic, can help people reduce alcohol consumption.
Alcohol is the most commonly misused substance in the UK, partly because it is legal, widely available and deeply ingrained in social culture. While many people can enjoy alcohol in moderation, a significant number struggle to control their drinking. For these people, excessive alcohol consumption can lead to serious physical, mental and social consequences.
Traditional treatments don't work for everyone, which is why we're exploring alternatives, such as psychedelics, that might enable people to change their behaviour in a single, transformative experience.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Join The Conversation for free today.
DMT is metabolised rapidly in the body. When administered intravenously, the effects kick in almost immediately, typically within one to two minutes. However, these effects are short-lived, lasting only ten to 20 minutes.
Despite its brief duration, many users describe the experience as intensely profound. They often report vivid visions, complex patterns and a sensation of entering a different reality. In some cases, the experience leads to a complete shift in how they think, feel and perceive the world. For many, the experience is deeply meaningful and transformative.
But what happens in the brain during this time, and how might it influence long-term behaviour, such as reducing alcohol consumption?
Read more:
Our team is particularly interested in how psychedelics like DMT might help in the context of addiction. One theory is that psychedelics can temporarily enhance neuroplasticity, the brain's ability to form new neural connections. This temporary boost could open a window of flexibility, allowing some people to be more open to change.
For someone stuck in the cycle of heavy drinking, this enhanced plasticity might help them break old habits and develop healthier behaviour. Essentially, it could offer the brain an opportunity to 'rewire' itself and disrupt the unhealthy patterns that underlie addiction.
We're also focusing on the brain's reward and motivation systems, which play a key role in addiction. These systems influence behaviour associated with pleasure, including eating, sex and drinking alcohol.
In people with alcohol use disorder, these systems become hypersensitive to alcohol-related cues, often at the expense of other rewarding experiences. Some early research suggests psychedelics may help 'reset' these reward pathways. We're testing this theory to see whether DMT can reduce alcohol consumption by recalibrating the brain's reward system.
To explore these possibilities, we've designed a study with heavy drinkers who are motivated to reduce their alcohol intake. Every participant undergoes a thorough screening to ensure they're fit for the study and all sessions are conducted in a highly controlled, clinical setting with medical professionals and experienced researchers overseeing the process.
The study involves three visits to our lab at UCL. On the first and third visits, we use functional magnetic resonance imaging (fMRI) to measure brain activity and observe how different regions of the brain interact.
During the scans, participants watch emotionally engaging films, which offer a more natural way to study brain responses compared to abstract tasks. This helps us assess how DMT might impact brain function in real-life, emotionally charged situations.
On the second visit, participants are randomly assigned to receive either DMT, a placebo, or a non-psychedelic drug (D-cycloserine or Lisuride). These non-psychedelic substances are believed to promote neuroplasticity without inducing the full psychedelic effects of DMT.
The study is double-blind – neither the participants nor the researchers know which substance is being administered. This helps eliminate bias and ensures that the results are as reliable as possible.
Additionally, we measure changes in brain activity during the drug infusion using electroencephalography (EEG). EEG tracks the brain's electrical signals and could help us predict which participants are most likely to benefit from DMT.
Participants also complete a range of psychological assessments, including questionnaires and tasks that measure memory, attention, mood and decision-making. This data will help us understand how changes in brain function might relate to changes in drinking behaviour.
We're still in the process of collecting data, but we're excited to see whether DMT can lead to meaningful reductions in alcohol consumption. As researchers, it's crucial that we stay objective and allow the evidence to guide our conclusions. By keeping the study 'blinded' until all results are in, we ensure that our findings are unbiased and reliable.
If DMT proves effective in helping people reduce their alcohol consumption, particularly for those who have struggled with other treatments, it could pave the way for a new approach to addiction therapy. Even if the results are inconclusive, they will still provide valuable insights into the potential role of psychedelics in addiction treatment and open up new avenues for future research.
It's important to emphasise that this research is taking place in a safe, controlled environment. Psychedelics are potent substances, and their effects can be unpredictable, especially outside of clinical settings. They are not a 'magic bullet' and are not suitable for everyone. The controlled setting allows us to study their effects while minimising risk to participants.
That said, we believe psychedelics offer a unique opportunity to better understand the brain and its capacity for change. By examining how transformative experiences can influence behaviour, we hope to contribute to the development of more effective treatments for addiction and other mental health conditions.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Ravi Das receives research funding from the Biotechnology and Biological Sciences Research Council (UK), Academy of Medical Sciences (UK) and Wellcome Leap (USA).
Rebecca Harding does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
3 days ago
- Time Magazine
New Zealand Becomes Latest Government to Approve ‘Shrooms' for Medicinal Use
Psilocybin is a notorious hallucinogen found in ' magic mushrooms '—a federally controlled substance that the U.S. deems to have 'no currently accepted medical use' and 'a high potential for abuse.' But not everyone agrees with that assessment: New Zealand on Wednesday became the latest country to approve the use of the substance for therapeutic purposes. David Seymour, New Zealand's Associate Minister for Health, told reporters that the new policy, which allows a single approved psychiatrist to prescribe psilocybin to patients with treatment-resistant depression, represents a ' real breakthrough.' Seymour said that the psychiatrist, identified as Cameron Lacey, a professor at the University of Otago, 'has previously prescribed psilocybin in clinical trials and will operate under strict reporting and record-keeping requirements.' Seymour added that he is hoping more psychiatrists will apply for clearance to prescribe the drug to patients, though he clarified that the drug remains 'unapproved medicine.' At the same time as the psilocybin policy change was announced, New Zealand announced plans to loosen restrictions on melatonin, which is used to treat insomnia and is sold over the counter in many other places. As Seymour promised to expand access to treatments like melatonin and psilocybin, no specific date was set for when they will be available across the country. Where is the use of psilocybin for medicinal purposes legal? New Zealand is not alone in permitting the medicinal use of the drug. Australia, in July 2023, authorized specific psychiatrists to prescribe it for the treatment of certain mental health conditions. In Switzerland, using LSD, MDMA, and psilocybin in medicine has been legal since 2014, for both research and treatment of mental health conditions. And while the substance is generally illegal in Canada, regulated medical use is allowed under strict conditions. Even some states in the U.S. have allowed some degree of use. Oregon became the first state to legalize psilocybin's therapeutic use in 2020, though some cities have banned the drug. Still, in the state, access to the drug remains restricted: it may only be administered in a licensed psilocybin service center, and an administration session can cost up to $2,000, according to the Associated Press. Colorado also legalized the regulated use of psilocybin for medical use in a ballot measure in 2022, with the first licenses for dispensing it issued earlier this year. And in April, New Mexico legalized psilocybin's use in approved settings to treat certain medical conditions. Laws on the regulated medical use of psilocybin are also making their way through state legislatures like Minnesota and Massachusetts.
San Francisco Chronicle
3 days ago
- San Francisco Chronicle
Texas is leading psychedelic research for treating addiction, mental illness. Where is California?
In recent years, researchers have expressed renewed optimism that psychedelics can be used in therapeutic settings to help treat addiction and mental illness, intertwined crises that have devastated Californians. Yet the Golden State is falling behind Republican-led states like Texas and Indiana in expanding research on these promising therapies. Texas earlier this month agreed to invest $50 million in public funding to research the therapeutic potential of ibogaine, a powerful psychedelic that has shown promise in treating opioid addiction, depression and anxiety. The move by Texas lawmakers was described as one of the largest public investments in psychedelic medicine to date. At his signing ceremony, Texas Gov. Greg Abbott proclaimed that 'Texas is now leading the way in the United States for the evaluation of ibogaine as a potential medication that can help improve the lives of so many Americans." Last year, Indiana Gov. Eric Holcomb signed a law to create a new research fund for therapy using psilocybin, a naturally occurring psychedelic compound found in 'magic mushrooms.' Although the federal government has not approved ibogaine, or most psychedelics, for medical use, there's growing interest among researchers and veteran organizations to explore the therapeutic benefits of drugs like ibogaine, MDMA, LSD, ketamine and psilocybin. Some California organizations have made considerable strides, though there have been roadblocks. San Jose-based Lykos Therapeutics last year became the first company to get a psychedelic compound through the Federal Drug Administration's extensive drug review process for an MDMA-assisted therapy for PTSD but the agency instructed the company to conduct more clinical trials before potential approval. For years, people experiencing addiction and mental illness, including a growing number of veterans and first responders, have quietly traveled to psychedelic-assisted treatment clinics in Mexico. Early research has produced some encouraging results for using these substances to treat addiction and mental illness, including depression, anxiety and post-traumatic stress disorder. Most prominent California universities employ researchers participating in therapeutic psychedelic clinical trials, though they're funded by federal grants, philanthropic donors or private pharmaceutical companies. A 2024 study from Stanford Medicine, for instance, found that ibogaine, when administered safely, improved emotional processing and cognitive functioning in veterans with traumatic brain injuries. The new spotlight on the therapeutic potential of psychedelics comes amid national opioid addiction and mental health crises, where for decades research has lagged. California has not made any public investments to date in researching psychedelic medicine, though there have been several failed attempts in recent years. 'There is growing awareness and support. It just keeps hitting different kinds of walls,' said State Senator Scott Wiener, D- San Francisco, adding that 'California is falling behind.' Gov. Gavin Newsom in 2023 vetoed a bill authored by Wiener to decriminalize the use and possession of certain psychedelics. Newsom called psychedelic medicine 'an exciting frontier' and said that California would be 'on the front edge of leading it,' but urged lawmakers to bring the legislation back the following session with more of a therapeutic focus. Wiener followed Newsom's request and introduced a bill last year with therapeutic guidelines, but it failed in committee. Also in 2023, a Los Angeles-based physician filed paperwork for a $5 billion ballot initiative to create a new state agency for studying the effects of psychedelic-assisted therapy, but it was later withdrawn. Additionally, two other state senators, Josh Becker, D-Menlo Park, and Brian Jones, R-San Diego, sponsored legislation to create a pilot program for veterans and former first responders to access psychedelic treatment for mental health conditions. The measure failed to make it out of the legislature two years in a row. 'I don't know what's going on in California to tell you the truth,' Jones said. 'Senator Becker and I are committed to trying again. It's just a question of how far other states get ahead of us now.' The Texas initiative focuses specifically on research involving ibogaine, a psychedelic compound originating from an African root. Ibogaine was used for centuries in religious ceremonies, but more recently has attracted attention for its antidepressant properties and its apparent ability to reduce opioid cravings and withdrawal. Under the Texas law, the state will invest $50 million in state funds to establish a public-private partnership with a $50 million matching contribution from a drug developer to run FDA-approved clinical trials with ibogaine. The goal is to study its ability to treat opioid use disorder and any co-occurring mental health conditions. The legislation guarantees Texas maintains authority over the research and development and that the state receives at least 20% of profits from any ibogaine pharmaceutical resulting from the trials. David Olson, director of the UC Davis Institute for Psychedelics and Neurotherapeutics, said the investment in Texas was 'very encouraging for the field of psychedelic medicine' but questioned the decision by Texas lawmakers to go all in on ibogaine. 'I would have preferred to see legislation where a variety of different types of substances were considered and then they can move forward with whatever was deemed most appropriate,' Olson said. 'At this moment, there are still so many unanswered questions and we need a lot of basic science across the board.' Although ibogaine has shown some promising results in treating opioid addiction and mental illness, it has also caused heart damage and deaths to several patients. The drug is known to inhibit certain potassium channels, which can lead to cardiac arrhythmias, but ibogaine proponents argue that it can be mitigated through regular supervision, magnesium administration and cardiac monitoring. Researchers believe other psychedelics, notably psilocybin, have shown more efficacy and are closer to gaining approval by the FDA. 'Psychedelics have inherent potential to be of great value to people for whom standard treatments often prove ineffectual,' said Charles Grob, a professor of psychiatry and pediatrics at the UCLA School of Medicine. 'But investigators have to do their due diligence to optimize safety parameters.'
Yahoo
4 days ago
- Yahoo
Could faecal transplants cause long-term health problems?
Keeping a healthy mix of friendly microbes in the gut – known as eubiosis – is crucial for good health. When that delicate balance is thrown off – often by antibiotics, diet or illness – the result can be a range of issues, from digestive problems to more serious conditions like Crohn's disease, ulcerative colitis, and even neurological and metabolic disorders. One increasingly popular way to try to restore gut health is through faecal microbiota transplantation. This involves taking stool from a healthy person, isolating the beneficial microbes and putting them in a capsule (jokingly referred to as 'crapsules' or 'poo pills'). The hope is that the beneficial microbes in the pill will establish themselves in the patient's gut, thereby improving microbial diversity and function. Faecal transplants have been used to treat a wide array of conditions, including irritable bowel syndrome, Parkinson's disease, obesity and Type 2 diabetes. Although generally viewed as safe and effective, a new international study published in the journal Cell has raised some concerns. The scientists found that when the donor's microbes do not properly match the recipient's gut environment – a situation they describe as a 'mismatch' – the treatment can disrupt the body's metabolic and immune systems, possibly with long-lasting consequences. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. The term 'mismatch' comes from the world of organ transplants, where the recipient's body rejects the donor organ. In this case, the problem is that microbes from the donor's large intestine may not be suitable for other parts of the recipient's gut, especially the small intestine, where the microbial makeup is very different. To test this, researchers gave antibiotics to mice to disturb their natural gut microbes, then treated them with faecal transplants. They also tried transplanting microbes specifically from different parts of the small intestine. The mice were monitored for one to three months to track changes. They found that faecal transplants often led to regional mismatches – the wrong microbes ending up in the wrong place. This altered the mix and behaviour of the gut microbes in unexpected ways, disrupting energy balance and other functions. Biopsies from the gut and liver showed significant, lasting changes in how certain genes – particularly those linked to metabolism and immunity – were being expressed. The study did not specify exactly what kind of health issues might result from these genetic shifts. But the researchers are urging doctors to take greater care when using faecal transplants, particularly when it comes to dose, timing and possible side-effects. There may, however, be a better way forward. A newer method known as the 'omni microbial approach' involves transferring microbes from all parts of the intestine, not just the colon. This could help recreate a more balanced and natural gut environment, avoiding the local mismatches seen in standard faecal transplants. There is also growing interest in techniques that aim to 'terraform' the gut: deliberately reshaping specific regions with carefully selected microbes to restore normal function. This new research has certainly sparked debate around the safety of faecal transplants. But with alternative approaches already being developed, there is real hope that the benefits of gut-based treatments can still be delivered, without the risks. This article is republished from The Conversation under a Creative Commons license. Read the original article. Georgios Efthimiou does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
